Core Insights - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 14, purchasing 2.1 million shares at a price range of HKD 2.870 to HKD 2.940, totaling HKD 6.09 million [2] - The stock closed at HKD 2.850 on the same day, reflecting a decline of 2.40%, with a total trading volume of HKD 49.30 million [2] - Year-to-date, the company has conducted 15 buybacks, acquiring a total of 43 million shares for a cumulative amount of HKD 127 million [2] Buyback Details - The latest buyback on October 14 involved 210,000 shares, with a maximum price of HKD 2.940 and a minimum price of HKD 2.870, amounting to HKD 6.09 million [2] - Previous buybacks include: - October 10: 150,000 shares at a maximum price of HKD 2.970, totaling HKD 4.43 million [2] - October 8: 200,000 shares at a maximum price of HKD 2.880, totaling HKD 5.73 million [2] - October 6: 300,000 shares at a maximum price of HKD 2.930, totaling HKD 8.70 million [2] - September 23: 500,000 shares at a maximum price of HKD 2.960, totaling HKD 14.67 million [2] - The company has consistently engaged in buybacks throughout the year, indicating a strategy to support its stock price and return value to shareholders [2]

格隆汇10月14日丨石四药集团(02005.HK)公告，10月14日耗资609.08万港元回购210万股，每股回购价 2.87-2.94港元。 ...

石四药集团(02005)发布公告，该公司于2025年10月14日斥资609.08万港元回购210万股股份，每股回购 价格为2.87-2.94港元。 ...

智通财经APP讯，石四药集团(02005)发布公告，该公司于2025年10月14日斥资609.08万港元回购210万 股股份，每股回购价格为2.87-2.94港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 石四藥集團有限公司 呈交日期： 2025年10月14日 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | ...

Core Insights - The latest shareholder equity disclosures were made by CLASSIFIED GP, Prosperity REIT, Stone Four Pharmaceutical Group, Da Chang Group, and Wang Chen Technology Holdings on October 13, 2025 [1] Group 1: Shareholding Changes - VMS Investment completely divested from CLASSIFIED GP, reducing its holdings from 3.4 million shares to 0 shares, resulting in a holding percentage of 0% [2] - ESR Asset increased its stake in Prosperity REIT from 71.5981 million shares to 76.0546 million shares, raising its holding percentage to 3.70% [2] - Qu Jiguang slightly increased his holdings in Stone Four Pharmaceutical Group from 1.211 billion shares to 1.213 billion shares, maintaining a holding percentage of 41.08% [2] - Chen Bin's holdings in Da Chang Group remained unchanged at 277 million shares, with a holding percentage of 44.92% [2] - Beijing Zhuiyuan Wealth Capital reduced its holdings in Wang Chen Technology Holdings from 8.0364 million shares to 6.0273 million shares, resulting in a holding percentage of 4.22% [2] - Liu Chengmin's holdings in Wang Chen Technology Holdings decreased from 10.1794 million shares to 7.0988 million shares, with a holding percentage of 4.97% [2]

香港联交所最新数据显示，10月9日，China Pharmaceutical Company Limited增持石四药集团(02005)123 万股，每股作价2.96港元，总金额约为364.08万港元。增持后最新持股数目约为8.86304亿股，持股比例 为30.03%。 ...

智通财经APP获悉，香港联交所最新数据显示，10月9日，China Pharmaceutical Company Limited增持石 四药集团(02005)123万股，每股作价2.96港元，总金额约为364.08万港元。增持后最新持股数目约为 8.86304亿股，持股比例为30.03%。 ...

Core Points - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 10, purchasing 1.5 million shares at prices ranging from HKD 2.940 to HKD 2.970, totaling HKD 4.4295 million [2] - The stock closed at HKD 2.960 on the same day, reflecting a decrease of 0.67%, with a total trading volume of HKD 26.5166 million [2] - Year-to-date, the company has conducted 14 buybacks, acquiring a total of 40.90 million shares for a cumulative amount of HKD 121 million [2] Buyback Details - The latest buyback on October 10 involved 150,000 shares at a maximum price of HKD 2.970 and a minimum price of HKD 2.940, costing HKD 4.4295 million [2] - Previous buybacks include: - October 8: 200,000 shares at a maximum price of HKD 2.880, totaling HKD 5.7266 million [2] - October 6: 300,000 shares at a maximum price of HKD 2.930, totaling HKD 8.6989 million [2] - September 23: 500,000 shares at a maximum price of HKD 2.960, totaling HKD 14.6748 million [2] - September 12: 90,000 shares at a maximum price of HKD 3.060, totaling HKD 2.7511 million [2] - September 11: 600,000 shares at a maximum price of HKD 3.040, totaling HKD 18.1433 million [2] - June 5: 540,000 shares at a maximum price of HKD 2.800, totaling HKD 15.0958 million [2] - June 4: 345,000 shares at a maximum price of HKD 2.850, totaling HKD 9.7254 million [2] - June 2: 755,000 shares at a maximum price of HKD 2.780, totaling HKD 20.9838 million [2] - April 2: 280,000 shares at a maximum price of HKD 3.440, totaling HKD 9.5882 million [2] - January 16: 50,000 shares at a maximum price of HKD 3.210, totaling HKD 1.6011 million [2] - January 15: 160,000 shares at a maximum price of HKD 3.230, totaling HKD 5.1320 million [2] - January 14: 70,000 shares at a maximum price of HKD 3.250, totaling HKD 2.2593 million [2] - January 2: 50,000 shares at a maximum price of HKD 3.450, totaling HKD 1.7193 million [2]

石四药集团(02005)发布公告，于2025年10月10日该公司斥资442.95万港元回购150万股，回购价格为每 股2.94-2.97港元。 ...